BriaCell Therapeutics Income Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct '25 Oct 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021	Jul '20 Jul 31, 2020
Selling, General & Admin	5.24	6.15	7.94	7.27	4.96	1.51
Research & Development	17.88	27.18	15.34	8.02	2.02	2.43
Operating Income	-23.12	-33.33	-23.27	-15.29	-6.98	-3.94
Interest Expense	-	-	-	-	-	-0.03
Other Non-Operating Income (Expense)	0.3	28.4	2.97	-11.55	-6.84	-0.14
Total Non-Operating Income (Expense)	0.3	28.4	2.97	-11.55	-6.84	-0.17
Pretax Income	-22.82	-4.93	-20.3	-26.84	-13.82	-4.11
Net Income	-22.59	-4.79	-20.3	-26.84	-13.82	-4.11
Minority Interest in Earnings	-0.22	-0.14	-	-	-	-
Net Income to Common	-22.59	-4.79	-20.3	-26.84	-13.82	-4.11
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change (YoY)	516.46%	5.35%	0.81%	242.82%	533.09%	23.16%
EPS (Basic)	-76.72	-43.50	-195.00	-259.50	-459.00	-846.00
EPS (Diluted)	-76.72	-43.50	-195.00	-259.50	-459.00	-846.00
Free Cash Flow	-25.52	-24.58	-23.74	-12.48	-7.75	-1.27
Free Cash Flow Per Share	-37.74	-224.09	-228.03	-120.86	-257.22	-265.99
EBITDA	-23.12	-33.25	-23.26	-15.27	-6.96	-3.92
EBIT	-23.12	-33.33	-23.27	-15.29	-6.98	-3.94

Updated Oct 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.